Lucrezia Zumstein, Clinical Oncologist Specialist at Candiolo Cancer Institute IRCCS, shared a post on LinkedIn:
“Happy to share our latest publication in ESMO Open.
In this multinational real-world study, we explored the role of reintroducing cisplatin – gemcitabine – durvalumab after progression during durvalumab maintenance in advanced biliary tract cancer. Our findings suggest this strategy may benefit carefully selected patients and warrant prospective validation.
Grateful for this great teamwork.”
Title: Cisplatin-gemcitabine-durvalumab reintroduction in advanced biliary tract cancer: a multinational real-world analysis
Authors: S. Camera, A. Vogel, M. Rimini, M. Ikeda, O. Abidoye, J. Lucchetti, L. Antonuzzo, J. W. Kim, F. Nichetti, A. Saborowski, T. Pressiani, C. Vivaldi, I. G. Rapposelli, F. Peeters, C. Braconi, D. J. Pinato, E. Tamburini, C. Pircher, S. Tamberi, F. Castet, M. Verrico, A. Parisi, N. Couto, H. J. Chon, A. Martirena, A. Lamarca, M. Landriscina, F. Finkelmeier, E. Oneda, A. Avallone, E. Dell’Aquila, L. Perkhofer, I. H. Kim, V. Formica, C. M. de Sousa Pinto, I. Garajova, B. Kang, S. Corallo, E. Fenocchio, G. Farinea, A. Pastorino, A. Diana, Y. Changhoon, M. Schirripa, M. G. Rodriquenz, M. Scartozzi, L. Zumstein, M. Ghidini, G. W. Prager, G. Aprile, G. P. Spinelli, S. Yung-Yeh, S. L. Chan, E. Warmington, A. Lancianese, T. Satake, T. Bekaii-Saab, G. Giordano, D. Lavacchi, L. Passeri, M. Ferrara, F. Rossari, F. Lo Prinzi, M. Kang, A. A. Prete, S. Bozzarelli, M. Persano, G. Masi, R. Balsano, M. Niger, S. Lonardi, F. Salani, L. Fornaro, L. Rimassa, A. Casadei-Gardini
Other articles about ESMO on OncoDaily.